The prognostic significance of the Platelet-to-Lymphocyte Ratio (PLR) in patients with hepatocellular carcinoma (HCC) undergoing treatment with immune checkpoint inhibitors (ICIs) remains uncertain.
A systematic review and meta-analysis was conducted to assess the prognostic value of PLR in HCC patients receiving ICIs.
